Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT02684253
- Phase
- PHASE2
- Status
- Completed
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUG
- Stereotactic Body Radiation Therapy (SBRT) — RADIATION
Study Details
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer. Nivolumab has been approved by the FDA for the treatment of melanoma (a form of skin cancer) and lung cancer. It is currently under study for the treatment of head and neck squamous cell cancer.
Key Dates
- Start date
- Feb 11, 2016
- Status verified
- Jan 2021
- Primary completion
- Jan 22, 2021
- Completion
- Jan 22, 2021
Study Design
- Enrollment
- 65 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Nivolumab 3mg/kg IV every 2 weeksNivolumab 3mg/kg IV every 2 weeks
- Experimental: Stereotactic Body Radiotherapy & NivolumabImage Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab). Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity.
Primary Outcome Measure
Percentage of Participants With Overall Response Rate [ Time Frame: 96 weeks ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memoral Sloan Kettering Cancer Center | Basking Ridge | New Jersey | - | - |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Cancer Center @ Suffolk | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering at Mercy Medical Center | Rockville Centre | New York | - | - |
Find similar trials in Basking Ridge, NJ
By research site
Memoral Sloan Kettering Cancer Center· Basking Ridge, NJMemorial Sloan Kettering Monmouth· Middletown, NJMemorial Sloan Kettering Cancer Center @ Suffolk· Commack, NYMemorial Sloan Kettering Westchester· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NYMemorial Sloan Kettering at Mercy Medical Center· Rockville Centre, NY
Related Studies
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Los Angeles, California
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPHASE2 · Recruiting · Regeneron Pharmaceuticals · Orlando, Florida
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Tanabe Pharma America, Inc. · Los Angeles, California